XALATAN (latanoprost) by Viatris (2) is 2α analogue that is believed to reduce the iop by increasing the outflow of aqueous humor. Approved for ocular hypertension, open-angle glaucoma, glaucoma. First approved in 1996.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
XALATAN (latanoprost) is a prostaglandin F2α analog ophthalmic solution that reduces intraocular pressure (IOP) by increasing uveoscleral outflow of aqueous humor. It is indicated for open-angle glaucoma and ocular hypertension, conditions where elevated IOP is a major risk factor for optic nerve damage and visual field loss. Administered as daily eye drops, latanoprost is a foundational therapy in IOP management.
Product approaching loss of exclusivity; commercial teams likely focused on lifecycle extensions, authorized generics, or transition support rather than growth initiatives.
2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the…
Prostaglandin Analog
Worked on XALATAN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension
Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.
Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moViatris (2) is hiring 2 roles related to this product
XALATAN offers limited career growth due to LOE-approaching status and minimal active clinical pipeline; roles are primarily commercial (brand management, field sales, market access) focused on defending market share and managing generic transition. Career trajectory is defensive rather than expansive, with mobility better suited to generics companies or authorized generic transitions.